Skip to main content

Animations

MJFF Publications

5241 - 5250 of 8801 Results
Title
Year
  • Year
  • 2013
  • 2023
  • 2016
  • 2017
  • 2021
  • 2013
  • 2018
  • 2021
  • 2023
  • 2018
  • Summary Details
    OPEN
    Title: Cheek cell–derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2013.08.008
    Citation Count: 30
  • Summary Details
    OPEN
    Title: Two‐Year observational study of autonomic skin function in patients with Parkinson's disease compared to healthy individuals
    Journal Name: European Journal of Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1111/ene.15733
    Citation Count: 4
  • Summary Details
    RESTRICTED
    Title: Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.aad8858
    Citation Count: 68
  • Summary Details
    OPEN
    Title: Loss of α-Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons
    Journal Name: eneuro
    Publisher: Society for Neuroscience
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1523/eneuro.0216-16.2017
    Citation Count: 15
  • Summary Details
    OPEN
    Title: Native Separation and Metallation Analysis of SOD1 Protein from the Human Central Nervous System: a Methodological Workflow
    Journal Name: Analytical Chemistry
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1021/acs.analchem.1c01128
    Citation Count: 7
  • Summary Details
    RESTRICTED
    Title: Tissue transglutaminase in Alzheimer's disease – facts and fiction: a reply to “Tissue transglutaminase is a biochemical marker for Alzheimer's disease”
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2013.09.042
    Citation Count: 14
  • Summary Details
    OPEN
    Title: Disease progression models for dominantly-inherited Alzheimer’s disease
    Journal Name: Brain
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/brain/awy089
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Differentially expressed genes in Alzheimer’s disease highlighting the roles of microglia genes including OLR1 and astrocyte gene CDK2AP1
    Journal Name: Brain, Behavior, & Immunity - Health
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.bbih.2021.100227
    Citation Count: 52
  • Summary Details
    RESTRICTED
    Title: Transdermal Nicotine Treatment and Progression of Early Parkinson’s Disease
    Journal Name: NEJM Evidence
    Publisher: Massachusetts Medical Society
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1056/evidoa2200311
    Citation Count: 19
  • Summary Details
    OPEN
    Title: β2‐adrenoreceptor medications and risk of Parkinson disease
    Journal Name: Annals of Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/ana.25341
    Citation Count: 72
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.